Misregulated signaling pathways can lead to defects in cell growth and development and thus to cancers and birth defects. The mechanism of this misregulation can best be understood in the context of normal signaling; therefore the goal of the work describe here is to understand the normal function in a signaling pathway triggered by members of the Wnt ligand family. Activation of the Wnt pathway is important during development, aberrant activation has been implicated in the genesis of both colon cancer and melanoma. The Wnt signal cascade starts at the cell membrane when a secreted Wnt proteins binds to its cell surface receptor and initiates a series of reactions that propagate the signal through the cytoplasm to the nucleus. In the nucleus, the Wnt signal directs changes in gene expression via a complex consisting of beta-catenin and one of four Lymphoid Enhance Factor or T Cell Factor proteins (collectively, LEF/TCFs). Unfortunately, very little is known about how the beta- catenin. LEF/TCF complex forms or how it regulates gene expression. Based on our data and work from other groups, we have formulated a model for the activities of this complex. These sequences differ among the four LEF/TCFs and thus a test of our model will yield insights as to how Wnt can direct complex, yet finely tuned effectors through different beta-catenin. LEF/TCF complexes.
Specific Aim 1 describes experiments to define a transcription activation domain of beta-catenin and identify proteins that bind to this region. If the state hypothesis is correct, recruited proteins should participate in transcription activation.
Aim 2 describes experiments to define a region in LEF-1 that confers enhancing activities on the complex. This same domain may also recruit the transcription repressor Groucho, a test for its ability to antagonize the actions of beta-catenin will be examined.
Aim 3 describes experiments to assess the role of LEF/TCF DNA binding domain in the recruitment of beta catenin and, paradoxically, an antagonizing nuclear co-activator to promoters.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Cell Development and Function Integrated Review Group (CDF)
Program Officer
Knowlton, John R
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Irvine
Schools of Medicine
United States
Zip Code
Arce, Laura; Pate, Kira T; Waterman, Marian L (2009) Groucho binds two conserved regions of LEF-1 for HDAC-dependent repression. BMC Cancer 9:159
Theisen, Heidi; Syed, Adeela; Nguyen, Baochi T et al. (2007) Wingless directly represses DPP morphogen expression via an armadillo/TCF/Brinker complex. PLoS One 2:e142
Arce, L; Yokoyama, N N; Waterman, M L (2006) Diversity of LEF/TCF action in development and disease. Oncogene 25:7492-504
Jimenez, Judith; Jang, Gwendolyn M; Semler, Bert L et al. (2005) An internal ribosome entry site mediates translation of lymphoid enhancer factor-1. RNA 11:1385-99
Atcha, Fawzia A; Munguia, Jesus E; Li, Tony W H et al. (2003) A new beta-catenin-dependent activation domain in T cell factor. J Biol Chem 278:16169-75
Holcombe, R F; Marsh, J L; Waterman, M L et al. (2002) Expression of Wnt ligands and Frizzled receptors in colonic mucosa and in colon carcinoma. Mol Pathol 55:220-6
Hovanes, K; Li, T W; Munguia, J E et al. (2001) Beta-catenin-sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer. Nat Genet 28:53-7